High-sensitivity C-reactive protein and atherosclerosis: From theory to therapy

Clinical Biochemistry

Volumn 33, Issue 8, 2000, Pages 601-610

  Yu, Harry ^a   Rifai, Nader ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; C reactive protein; Inflammation; Myocardial infarction; Review; Risk factors; Unstable angina

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ALGORITHM; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CORRELATION FUNCTION; HEART INFARCTION; HUMAN; INFLAMMATION; LIPID STORAGE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; WESTERN HEMISPHERE;

EID: 0034477345     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(00)00186-7     Document Type: Article

References (63)

1. Macrophages, macrophage foam cells, and eccentric intimal thickening in the coronary arteries of young children
2. Determinants of atherosclerosis in the young
3. The pathogenesis of atherosclerosis: A perspective for the 1990s
4. Molecular basis of the acute coronary syndromes
5. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
6. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events
7. Elevated levels of interleukin-6 in unstable angina
8. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
9. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
10. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
11. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men
12. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus
13. Isolation of human C-reactive protein complementary RNA and localization of the gene to chromosome 1
14. Primary structure of human C-reactive protein
15. Low-grade acute-phase reactions in arteriosclerosis and the consequences for haemostatic risk factors
16. C-reactive protein fifty years on
17. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
18. Hormone replacement therapy and increased plasma concentration of C-reactive protein
19. Effect of postmenopausal hormones on inflammation-sensitive proteins: The post menopausal estrogen/progestin interventions (PEPI) study
20. Proteolysis of human C-reactive protein produces peptides with potent immunomodulating activity
21. Antiinflammatory properties of hepatic acute phase proteins: Preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1+ synthesis by human peripheral blood mononuclear cells
22. Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis
23. Interaction of C-reactive protein complexes with the complement system. I: Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with choline phosphatides, lecithin and sphigomyelin
24. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement
25. Complement activation by C-reactive protein complexes
26. C-reactive protein co-localizes with complement in human hearts during acute myocardial infarction
27. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
28. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease
29. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease
30. Measurement of serum C-reactive protein concentration in myocardial ischemia and infarction
31. Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction
32. C-reactive protein as a predictor of cardiac rupture after a first Q wave acute myocardial infarction
33. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction
34. Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy
35. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic therapy
36. Production of C-reactive protein and risk of coronary events in stable and unstable angina
37. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease
38. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
39. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy
40. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction
41. Independent prognostic value of elevated C-reactive protein in unstable angina
42. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
43. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
44. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The cholesterol and recurrent events (CARE) trial
45. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
46. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty
47. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis. Chimeric c7E3 antiplatelet therapy in unstable angina refractory to standard treatment trial
48. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events
49. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
50. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
51. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
52. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
53. Relationship of C-reactive protein to the risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project
54. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
55. Evaluation of four automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications
56. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A, and mannose-binding protein in human serum
57. A proposed cardiovascular risk assessment algorithm employing high-sensitivity C-reactive protein and lipid screening
58. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological application
59. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
60. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
61. Long-term effects of pravastatin concentrations of C-reactive protein
62. Pravastatin sodium endothelial nitric oxide synthase independent of its cholesterol-lowering actions